IN FOCUS: Solvias
Pharmaceutical Technology
DECEMBER 9, 2022
The move is particularly timely given the significant growth expected in global sales of cell and gene therapies. Solvias has extensive experience with analytical method development and testing for mRNA-based vaccines as well as monograph testing of excipients and APIs according to Ph Eur or USP.
130 
Let's personalize your content